Status:
COMPLETED
Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia
Lead Sponsor:
NYU Langone Health
Conditions:
Tachycardia, Ventricular
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Determine effects of remifentanil conscious sedation in patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia and/or persistent frequent prematur...
Detailed Description
The purpose of the study is to determine the effects of remifentanil conscious sedation in patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia ...
Eligibility Criteria
Inclusion
- Patients scheduled to undergo EP studies for the ablation of idiopathic ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin
- Patients between 18 and 65
- ASA 1-3
Exclusion
- ASA 4 and 5
- Age 18 and 65
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01901575
Start Date
July 1 2011
End Date
April 1 2013
Last Update
January 2 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU Langone Medical Center
New York, New York, United States, 10016